Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H19NO2 |
Molecular Weight | 233.3062 |
Optical Activity | ( + ) |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C2CCCC2=C1O[C@H]3CCNC3
InChI
InChIKey=QDJAYXYEXHVXJV-NSHDSACASA-N
InChI=1S/C14H19NO2/c1-16-13-6-5-10-3-2-4-12(10)14(13)17-11-7-8-15-9-11/h5-6,11,15H,2-4,7-9H2,1H3/t11-/m0/s1
Molecular Formula | C14H19NO2 |
Molecular Weight | 233.3062 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
ORG 37684 is a selective full agonist of 5-hydroxytryptamine receptor 5-HT2 family with a high selectivity for 5-HT2C in comparison with 5-HT2B and 5-HT2A receptors. It was studied for treatment of depression, but that investigations were discontinued. On animal studies ORG 37684 possessed hypophagic effect, which was exclusively mediated by activation of 5-HT2C receptors. Thus, this compound can be further investigated in using for weight loss.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10498829 |
7.11 null [pEC50] | ||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10498829 |
8.17 null [pEC50] | ||
Target ID: CHEMBL1833 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10498829 |
7.96 null [pEC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11999893
in rats: 1.84 mg/kg
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12569067
To examine the effect of receptor density on agonist efficacy, three agonists of differential efficacies were examined for GTPγ35S binding; a full agonist, Org37684, a partial agonist, quipazine, and a weak partial agonist LSD. Enhancement of GTPγ35S binding by Org37684 (10 μM) ranged from 93 to 101% as normalized to that of 5-HT (10 μM), quipazine from 52 to 67%, and LSD from 23 to 29% in these cell lines, with no appreciable dependence on receptor density.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 19:09:01 GMT 2023
by
admin
on
Sat Dec 16 19:09:01 GMT 2023
|
Record UNII |
48QQ8ZTE6C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
48QQ8ZTE6C
Created by
admin on Sat Dec 16 19:09:01 GMT 2023 , Edited by admin on Sat Dec 16 19:09:01 GMT 2023
|
PRIMARY | |||
|
9794656
Created by
admin on Sat Dec 16 19:09:01 GMT 2023 , Edited by admin on Sat Dec 16 19:09:01 GMT 2023
|
PRIMARY | |||
|
ORG-37684
Created by
admin on Sat Dec 16 19:09:01 GMT 2023 , Edited by admin on Sat Dec 16 19:09:01 GMT 2023
|
PRIMARY | |||
|
436083-07-7
Created by
admin on Sat Dec 16 19:09:01 GMT 2023 , Edited by admin on Sat Dec 16 19:09:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|